US/UK/Canada

Share

Quotes

Musculoskeletal pain is a big health issue affecting quality of life for the vast majority of the population. As a health issue, it deserves more attention, and we have seen the need for more insights and knowledge. On the ThermaCare® website we will provide articles and interviews on this important subject, as well as information about ThermaCare as an effective and drug-free pain relief
Astrid T. Bratvedt
The addition of the antibiotics portfolio marked an important milestone for Navamedic and our expanding hospital and prescription drug offering. We are pleased to welcome Icepharma to join us in securing steady supply of these important products to Nordic hospitals,
says Kathrine Gamborg Andreassen, CEO of Navamedic.
Pick a time period -
Tags ( Active)

Navamedic Q3 2024: Business remains strong in quarter impacted by cyclical nature of the business

Oslo, 31 October 2024 – In the third quarter of 2024, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, delivered revenues of NOK 123.1 million compared to 141.0 in the corresponding quarter last year. Adjusted EBITDA amounted to NOK 8.6 million compared to NOK 17.4 million in 2023. Gross margin ended at 37.1 per cent, slightly down from 37.6 per cent in the third quarter of 2023.During the quarter, Navamedic has continued its steady operational progress across its three segments: Prescription Drugs (RX), Consumer

Navamedic ASA: Invitation to 2024 3rd quarter presentation

Oslo, October 28, 2024 - Navamedic ASA (OSE: Nava) will be presenting its 3rd quarter 2024 results on Thursday, October 31st, 2024. The presentation will be held at Haakon VIIs gate 2 in Oslo and the event will start at 08.30 CET. A link to the webcast and the presentation will be available through the Navamedic web site on the following link: https://navamedic.com/investors/financial -results/ For further information, please contact: Kathrine Gamborg Andreassen, CEO, +47 951 78 680 E-mail: kathrine@navamedic.com Lars Hjarrand, CFO, +47 917 62 842 E-mail: lars.hjarrand@navamedic.

Navamedic wins joint Nordic antibiotics tender

Oslo, 07 October 2024 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, has signed joint contracts with Amgros in Denmark, Landspitali Háskólasjúkrahús in Iceland and Sykehusinnkjøp HF, divisjon legemidler in Norway to be the main supplier of certain antibiotics to hospital across all three countries. The contracts start in April 2025 and will run until 2027, with the opportunity for an extension.These are the latest of several tenders Navamedic has secured this year, representing significant growth for the

Navamedic announces an exclusive agreement with Alex Therapeutics for the development of a Companion App to aid in the treatment of Parkinson’s Disease

Stockholm Sweden, September 12, 2024 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, has partnered with Alex Therapeutics, a digital health provider of disease and drug companion apps, to aid in Parkinson’s treatment management. The app will be developed by Alex Therapeutics to support patients on Flexilev®, a prescription treatment for Parkinson’s disease.The new companion app provides medication management support that addresses the specific needs and challenges of people living with Parkinson’s disease. The

Navamedic ASA – Mandatory notification of trade by primary insider

Oslo, 9 September 2024: Reference is made to the stock exchange announcement published earlier today, on 9 September 2024 by Navamedic ASA (the "Company" or "Navamedic"), regarding the board of directors' resolution to increase the Company's share capital with NOK 170,200 by the issuance of 230,000 new shares, in order to facilitate the settlement of exercise of 230,000 share options in the Company. The following primary insiders have today exercised share options: Kathrine Gamborg Andreassen, CEO of Navamedic, has today, on September 9 2024, exercised 80,000 share options in the

NAVAMEDIC ASA: RESOLUTION TO INCREASE THE SHARE CAPITAL IN CONNECTION WITH EXERCISE OF EMPLOYEE OPTIONS

Oslo, 9 September 2024: The board of directors of Navamedic ASA (the "Company"), has today, on 9 September 2024, in accordance with the authorisation granted to it by the general meeting on 4 June 2024, resolved to increase the Company's share capital by NOK 170,200 by issuance of 230,000 new shares, each with a nominal value of NOK 0.74, in order to facilitate the settlement of exercise of 230,000 share options. The exercise price is NOK 19.00 per share for the 230,000 new shares. Following the registration of the share capital increase with the Norwegian Register of Business

Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new licensing and supply agreement

Oslo, 16 August 2024 – In first half of 2024, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, delivered revenues of NOK 277.2 million, up 12.8 per cent from the corresponding period last year. Adjusted EBITA amounted to NOK 41.1 million compared to NOK 26.3 million in 2023. The milestone payment of NOK 22.7 million following the agreement with Orion Corporation to market and sell Flexilev® and OraFID® in Europe is included.During the first six months of 2024, Navamedic has delivered on its strategy across the

Navamedic ASA: Invitation to 2024 2nd quarter presentation

Oslo, August 12, 2024 - Navamedic ASA (OSE: Nava) will be presenting its 2nd quarter/1st half 2024 results on Friday, August 16, 2024. The presentation will be held at Haakon VIIs gate 2 in Oslo and the event will start at 08.30 CET. A link to the webcast and the presentation will be available through the Navamedic web site on the following link: https://navamedic.com/investors/financial-results/ For further information, please contact: Kathrine Gamborg Andreassen, CEO, +47 951 78 680 E-mail: kathrine@navamedic.com Lars Hjarrand, CFO, +47 917 62 842 E-mail: lars.hjarrand@navamedic.

Navamedic and Orion Corporation sign License & Supply Agreement for Flexilev® in Europe

Oslo, 24 June 2024 - Navamedic ASA and Orion Corporation (“Orion”) have today signed a license and supply agreement for Flexilev®, including the OraFID® dispenser, across Europe, not including Sweden, Norway, Denmark, and Iceland, where Navamedic will market and sell the product. Flexilev is a novel prescription treatment for Parkinson’s disease and was added to Navamedic’s product portfolio following the acquisition of Sensidose AB in May 2023. Through the signed agreement, Orion has been granted the exclusive right to market, distribute, and sell Flexilev® in 27 countries in Europe,

Navamedic ASA: Minutes of Annual General Meeting

Oslo, 4 June 2024: The Annual General Meeting of Navamedic ASA was held today at 09:00 CEST. All items on the agenda were resolved in accordance with the board of directors' proposals and the nomination committee's recommendations. A copy of the minutes from the Annual General Meeting is attached to this notice and will also be made available on the Company's webpage www.navamedic.com. This information is subject of the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. For further information, please contact: Kathrine G. Andreassen, CEO,

Navamedic ASA: Renewed contract for delivering antibiotics to Norwegian hospitals

Oslo, 16 May 2024 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, has received confirmation of an extension of its contract with The Norwegian Hospital Procurement Trust (Sykehusinnkjøp HF) for continued delivery of antibiotics to Norwegian hospitals. The contract runs to 31 January 2027. The contract is awarded by The Norwegian Hospital Procurement Trust on behalf of the four health regions in Norway as part of the LIS tender programme (in Norwegian: legemiddelinnkjøpssamarbeid) for antibiotics. The

Navamedic ASA: Notice of Annual General Meeting

The annual general meeting of Navamedic ASA (OSE: NAVA) will be held on Tuesday, June 4th 2024 at 09:00 (CET) in the Navamedic offices in Henrik Ibsens gate 100, 0255 Oslo. The Notice of the Annual General Meeting is attached. The Notice is posted electronically or by mail to all shareholders and is available on the company's website https://navamedic.com/investors/general-meeting/. For further information, please contact: Kathrine G. Andreassen, CEO, Navamedic, Mobile: +47 951 78 680 E-mail: kathrine@navamedic.com Lars Hjarrand, CFO, Navamedic, Mobile: +47 917 62 842 E-mail: lars.

Navamedic ASA: Broad launch for Eroxon® in Sweden today

Oslo, 6 May 2024 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies has launched Eroxon® in Sweden. Eroxon® is clinically proven and considered a breakthrough in treatment of erectile dysfunction for men and will be the first non-prescription treatment for erectile dysfunction in the Swedish market.Eroxon® was launched in Norway in February 2024 and has been very well received by Norwegian consumers. After only two weeks in the market, it was the bestseller at an online pharmacy. Strong sales resulted in Eroxon®

Navamedic ASA: Annual Report 2023

Oslo, 30 April 30 2024 -  Navamedic ASA has today published its Annual Report for 2023 approved by the Board of Directors. Find enclosed the report in PDF as well as an ESEF file version. The report is also made available at the company's website at    https://navamedic.com/investors/annual-reports/ For further information, please contact: Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail: kathrine@navamedic.com Lars Hjarrand, CFO, Navamedic Mobile: +47917 62 842 E-mail: lars.hjarrand@navamedic.com About Navamedic Navamedic ASA is a full-service

Navamedic Q1 2024: Successful product launch and steady operational progress

Oslo, 30 April 2024 – In the first quarter 2024, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, had revenues of NOK 121 million and an adjusted EBITDA of NOK 8.5 million. Revenues were at the same level as last year. Adjusted EBITDA was in line with the previous quarter, but below last year.   The company had steady operational progress and rolling 12 months revenues increased 15 percent year-over-year. The first three months of 2024 were marked by normal fluctuation in revenue between quarters, due to

Navamedic ASA – Mandatory notification of trade by primary insider

Oslo, 15 March 2024: Reference is made to the stock exchange announcement published earlier today, on 15 March 2024 by Navamedic ASA (the "Company" or "Navamedic"), regarding the board of directors' resolution to increase the Company's share capital with NOK 59,200 by the issuance of 80,000 new shares, in order to facilitate the settlement of exercise of 80,000 share options in the Company. The following primary insiders have today exercised share options: Lars Hjarrand, CFO of Navamedic, has today, on March 15 2024, exercised 50,000 share options in the Company under his option

Navamedic ASA: Resolution to increase the share capital in connection with exercise of employee options

Oslo, 15 March 2024: The board of directors of Navamedic ASA (the "Company"), has today, on 15 March 2024, in accordance with the authorisation granted to it by the general meeting on 1 June 2023, resolved to increase the Company's share capital by NOK 59,200 by issuance of 80,000 new shares, each with a nominal value of NOK 0.74, in order to facilitate the settlement of exercise of 80,000 share options. The exercise prices are NOK 19.00 per share for the 80,000 new shares. Following the registration of the share capital increase with the Norwegian Register of Business Enterprises (Nw.:

Navamedic welcomes new shareholders

Oslo, 13 March 2024: Navamedic (OSE: NAVA) is pleased to welcome new shareholders and delighted to see existing shareholders acquire a bigger stake following Ingerø Reiten Investment Company’s (IRIC) sale of its entire 17.1 percent interest in the company. “IRIC has been an active owner in Navamedic since December 2018 when it became our largest shareholder.  During this period, we have transformed the company into a profitable business with an attractive product portfolio, well positioned for future growth. We have appreciated the cooperation and good support from IRIC,” said Kathrine

Navamedic ASA: Notification of major shareholding and mandatory notification of trade

Oslo, 12 March 2024 - Ingerø Reiten Investment Company AS ("IRIC") has today sold all of its shares in the Nordic pharmaceutical company Navamedic ASA. The shares were sold for 32 kroner per share, for total gross proceeds of approximately NOK 95 million, or about 2.7 times the amount invested. IRIC has been Navamedic's principal owner and strategic partner since 2019. IRIC will use part of the proceeds to strengthen its balance sheet by paying off debt. "For IRIC this was the right time to sell. Navamedic is a first-class company, but as a large, strategic investor, it is also important

Navamedic ASA: Mandatory notification of trade

Åsa Kornfeld and Edmée Steenken, both primary insiders and Board members in Navamedic ASA, have on 22 February 2024 purchased shares in Navamedic ASA. Åsa Kornfeld bought 2,679 shares at an average price of NOK 36.80 per share. Edmée Steenken bought 10,000 shares at an average price of NOK 37.45 per share. See more details in the attached notification form. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

Navamedic Q4 and full year 2023: A year marked by new records and transformative growth initiatives

Oslo, 15 February 2024 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announced its results for the fourth quarter and for the full year 2023. Revenues for the year was up 34 per cent to NOK 512 million, mainly by organic growth. For the first time all three product categories were above the NOK 100 million mark.The company’s gross margin was 38.9 per cent for the year, down from 42.8 per cent in the year before. Adjusted EBITDA (EBITDA less acquisition cost) amounted to NOK 51.6 million, compared with

Navamedic ASA: Invitation to 2023 4th quarter presentation

Oslo, February 13, 2024 - Navamedic ASA (OSE: Nava) will be presenting its fourth quarter 2023 results on Thursday, February 15, 2024. The presentation will be held at Dronning Eufemias gate 16 in Oslo and the event will start at 08.30 CET. A link to the webcast and the presentation will be available through the Navamedic web site on the following link: https://navamedic.com/investors/financial-results/ For further information, please contact: Kathrine Gamborg Andreassen, CEO, +47 951 78 680 E-mail: kathrine@navamedic.com Lars Hjarrand, CFO, +47 917 62 842 E-mail: lars.hjarrand@

Navamedic ASA launches Eroxon®

Oslo, 12 February 2024 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, has acquired rights to market and distribute Eroxon® in the Nordic countries. Eroxon® is clinically proven and considered a breakthrough in treatment of erectile dysfunction for men.Already a success in pharmacies in the UK, the product was launched in Norway this week. It can be bought online and at pharmacies across the country without a doctor’s prescription. Roll-out in Sweden is being planned in May this year. Denmark and Finland will

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe